Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY)Zacks Investment Research • 03/05/25
Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdatesGlobeNewsWire • 02/26/25
Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025GlobeNewsWire • 02/19/25
Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/25
Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 12/20/24
Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free SurvivalGlobeNewsWire • 12/11/24
Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer SymposiumGlobeNewsWire • 12/09/24
After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY)Zacks Investment Research • 12/06/24
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsGlobeNewsWire • 12/03/24
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid TumorsGlobeNewsWire • 12/03/24
Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a TurnaroundZacks Investment Research • 11/20/24
Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a TurnaroundZacks Investment Research • 11/19/24
Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate HighlightsGlobeNewsWire • 11/06/24
Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024GlobeNewsWire • 10/30/24
Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength?Zacks Investment Research • 09/17/24
Relay Therapeutics' RLY-2608 Shows Promise For Breast Cancer With PI3Kα MutationsSeeking Alpha • 09/11/24
GameStop Reports Weak Sales, Joins Petco, Relay Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga • 09/11/24
Relay Therapeutics Faces Downgrade Over Efficacy Concerns in Competitive PI3K Inhibitor MarketBenzinga • 09/10/24
This Johnson Controls International Analyst Turns Bullish; Here Are Top 5 Upgrades For TuesdayBenzinga • 09/10/24